Early research
Glucagon-like peptide-1 (GLP-1) is a hormone made in the gut after eating. In the early 1980s, scientists found that the gene for the hormone glucagon also codes for GLP-1. In 1986 and 1987, researchers in Boston showed that a short form of GLP-1 is made in the intestine and strongly boosts insulin release. In 2024, three scientists behind this work and the later drug research received the Lasker-DeBakey Clinical Medical Research Award.
Natural GLP-1 breaks down in the body within minutes, so it could not be used as a drug by itself. In 1992, a team led by John Eng reported exendin-4, a peptide found in the saliva of the Gila monster that acts like GLP-1 but lasts longer. You can read more in exenatide and the Gila monster.
Diabetes medicines
Exenatide, a lab-made version of exendin-4, was approved by the FDA as Byetta on April 28, 2005 for type 2 diabetes. It was the first GLP-1 receptor agonist on the US market. Liraglutide (Victoza) followed in 2010 as a once-daily shot. A once-weekly form of exenatide (Bydureon) came in 2012, and dulaglutide (Trulicity) in 2014.
Semaglutide was approved as Ozempic, a weekly shot, in December 2017. In 2019, Rybelsus became the first GLP-1 tablet, also for type 2 diabetes. In May 2022, the FDA approved tirzepatide as Mounjaro. Tirzepatide acts on both the GLP-1 and GIP receptors.
Weight-loss medicines
Liraglutide was the first GLP-1 drug approved for chronic weight management, as Saxenda in December 2014. Semaglutide followed as Wegovy on June 4, 2021, and tirzepatide as Zepbound on November 8, 2023.
From 2024, labels grew to cover other conditions. Wegovy was approved to lower the risk of heart attack, stroke and heart-related death in March 2024. Zepbound became the first drug approved for moderate to severe obstructive sleep apnea in adults with obesity in December 2024. Ozempic gained a kidney disease indication in January 2025, and Wegovy an approval for a form of fatty liver disease (MASH) in August 2025.
Pills for weight loss
On December 22, 2025, the FDA approved the Wegovy pill, a daily oral semaglutide tablet, as the first GLP-1 pill for weight management. On April 1, 2026, the FDA approved orforglipron as Foundayo, a daily pill that is a small molecule rather than a peptide. To see how the current medicines compare with each other, visit our GLP-1 medication comparison.
Timeline
- 1982-1983Researchers find that the proglucagon gene also codes for GLP-1. (PNAS 2024, The discovery and development of GLP-1 based drugs)
- 1986-1987GLP-1(7-37) is identified in the intestine and shown to strongly stimulate insulin release. (PNAS 2024, The discovery and development of GLP-1 based drugs)
- April 15, 1992John Eng and colleagues publish the isolation of exendin-4 from Gila monster saliva. (Eng et al., J Biol Chem 1992 (PMID 1313797))
- April 28, 2005Byetta (exenatide), the first GLP-1 receptor agonist, is approved for type 2 diabetes. (Drugs@FDA, NDA 021773)
- January 25, 2010Victoza (liraglutide) is approved for type 2 diabetes. (Drugs@FDA, NDA 022341)
- January 27, 2012Bydureon, a once-weekly exenatide, is approved. (Drugs@FDA, NDA 022200)
- September 18, 2014Trulicity (dulaglutide) is approved for type 2 diabetes. (Drugs@FDA, BLA 125469)
- December 23, 2014Saxenda (liraglutide) becomes the first GLP-1 drug approved for chronic weight management. (Drugs@FDA, NDA 206321)
- December 5, 2017Ozempic (semaglutide) is approved as a weekly shot for type 2 diabetes. (Drugs@FDA, NDA 209637)
- September 20, 2019Rybelsus becomes the first GLP-1 tablet, for type 2 diabetes. (Drugs@FDA, NDA 213051)
- June 4, 2021Wegovy (semaglutide 2.4 mg) is approved for chronic weight management. (Drugs@FDA, NDA 215256)
- May 13, 2022Mounjaro (tirzepatide), the first dual GIP and GLP-1 receptor agonist, is approved for type 2 diabetes. (Drugs@FDA, NDA 215866)
- November 8, 2023Zepbound (tirzepatide) is approved for chronic weight management. (Drugs@FDA, NDA 217806)
- March 8, 2024Wegovy is approved to reduce the risk of major heart events in adults with heart disease and obesity or overweight. (FDA press release, March 8, 2024)
- September 2024GLP-1 researchers Joel Habener, Svetlana Mojsov and Lotte Bjerre Knudsen receive the Lasker-DeBakey award. (JCI 2024;134(19):e186225)
- December 20, 2024Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity. (FDA press release, December 20, 2024)
- January 28, 2025Ozempic is approved to reduce kidney and heart risks in adults with type 2 diabetes and chronic kidney disease. (Novo Nordisk announcement)
- August 15, 2025Wegovy receives accelerated approval for MASH with moderate to advanced liver fibrosis. (Novo Nordisk Form 6-K, August 15, 2025)
- December 22, 2025The Wegovy pill (oral semaglutide 25 mg) is approved as the first GLP-1 pill for weight management. (Novo Nordisk announcement, December 22, 2025)
- April 1, 2026Foundayo (orforglipron), a daily non-peptide GLP-1 pill, is approved for weight management. (FDA press release, April 1, 2026)
Compare today's GLP-1 medicines
See also
References
- Drucker DJ, Habener JF, Holst JJ, "The discovery and development of GLP-1 based drugs", PNAS 2024. doi.org
- Eng J et al., "Isolation and characterization of exendin-4", J Biol Chem 1992. pubmed.ncbi.nlm.nih.gov
- Drugs@FDA, Byetta (NDA 021773). accessdata.fda.gov
- FDA, "FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight" (March 8, 2024). fda.gov
- FDA, "FDA Approves First Medication for Obstructive Sleep Apnea" (December 20, 2024). fda.gov
- FDA, "FDA Approves First New Molecular Entity Under National Priority Voucher Program" (April 1, 2026). fda.gov
Last updated . Category: History & timeline. Browse all 38 WikiTelehealth entries.